Estrella Immunopharma Expands Clinical Trial for EB103 ARTEMIS T-Cell Therapy in NHL

Jun 05 , 2025

Emeryville, California, June 5, 2025 – Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, announced the activation of a second clinical site for its STARLIGHT-1 Phase I/II clinical trial. The trial is evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). The new site, Baylor Research Institute d/b/a Baylor Scott & White Research Institute in Dallas, Texas, is now enrolling patients.

Cheng Liu, CEO of Estrella, stated that this partnership with Baylor Research Institute is a crucial step in expanding the reach of the STARLIGHT-1 trial. He believes this expansion will accelerate development and improve patient access to EB103, aligning with the company’s goal of providing safer and more effective treatments for advanced NHL.

The STARLIGHT-1 trial (NCT06343311) is an open-label, dose escalation, multi-center, Phase I/II clinical trial. Its primary objectives are to assess the safety of EB103 autologous T-cell therapy and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) with relapsed/refractory (R/R) B-cell NHL. The study consists of a dose escalation phase followed by an expansion phase.

EB103, also known as Estrella’s “CD19-Redirected ARTEMIS® T-Cell Therapy,” utilizes ARTEMIS® technology licensed from Eureka Therapeutics, Inc., Estrella’s parent company. The ARTEMIS® T-Cell is designed to be activated and regulated upon engagement with cancer targets in a manner that more closely resembles the mechanism of an endogenous T-cell receptor, unlike traditional CAR-T cells. Once infused, EB103 T-cells specifically target and destroy CD19-positive cancer cells.

Source:

https://www.estrellabio.com/news/estrella-immunopharma-announces-activation-of-additional-site-for-phase-i%2Fii-starlight-1-trial-in-b-cell-non-hodgkin%E2%80%99s-lymphoma

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.